MedTrace Logo

Cell Therapy in Chagas Cardiomyopathy

NCT00349271 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2017-03-13

No results posted yet for this study

Summary

The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy

Conditions

  • Chagas Cardiomyopathy

Interventions

PROCEDURE

Stem cell

Stem cell

DRUG

Filgrastime (G-CSF)

Filgrastime (G-CSF)

DRUG

Standart therapy

All drug with clinical evidence of benefical effect in Chagas disease

Sponsors & Collaborators

  • Financiadora de Estudos e Projetos

    collaborator OTHER

  • Ministry of Health, Brazil

    lead OTHER_GOV

Principal Investigators

  • Ricardo R Santos, MD,PhD · Centro de pesquisa Gonzalo Muniz

  • Gilson Feitosa, MD · Hospital Santa Isabel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2010-12-31
Completion
2011-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349271 on ClinicalTrials.gov